| | 926037-48-1 Basic information More.. |
| Product Name: | Radotinib | | Synonyms: | IY5511;Radotinib;Radotinib(IY-5511);4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide;4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phe...;Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(2-pyrazinyl)-2-pyrimidinyl]amino]-;RADOTINIB; IY5511 HCL.;IY5511 HCl. | | CAS: | 926037-48-1 | | MF: | C27H21F3N8O | | MW: | 530.5 | | EINECS: | | | Mol File: | 926037-48-1.mol |  |
Use
Radotinib, an inhibitor of Bcr–Abl tyrosine kinase,was approved in January 2012 in Korea as a second-line treatment for chronic myeloid leukemia (CML).
Radotinib is a TKI with a similar structure to the second-generation TKI, nilotinib, in which a pyridyl group has been replaced with a pyrazinemoiety. The in vitro activity of radotinib against a variety of tumor cell lines is disclosed in an issued patent. Radotinib was significantly more potent than imatinib in all of the cell lines tested. The synthesis of radotinib via amide coupling is described in the patent literature.
- Radotinib
-
- US $1.00 / KG
- 2019-12-26
- CAS:926037-48-1
- Min. Order: 1KG
- Purity: ≥98%
- Supply Ability: g/kg/Ton
|
|
926037-48-1
Recommend Suppliers |
|